Pharmaceutical Research

, Volume 28, Issue 5, pp 1167–1178 | Cite as

Octreotide-Modified Polymeric Micelles as Potential Carriers for Targeted Docetaxel Delivery to Somatostatin Receptor Overexpressing Tumor Cells

  • Yuan Zhang
  • Xueqing Wang
  • Jiancheng Wang
  • Xuan Zhang
  • Qiang Zhang
Research Paper



Somatostatin analogue octreotide (OCT)-modified PEG-b-PLA micelles were constructed to bind to somatostatin receptors (SSTRs) overexpressed on tumor cells for enhanced intracellular drug delivery and improved therapeutic efficacy for malignant tumors.


Copolymers conjugated with octreotide (OCT-PEG6000-b-PLA5000) were synthesized. The fluorescent probe DiI or docetaxel (DTX)-loaded micelles with or without octreotide modification (OCT-PM-DiI, PM-DiI, OCT-PM-DTX and PM-DTX) were prepared, and their physiochemical properties, intracellular delivery in vitro or anti-tumor activity in vivo were evaluated, respectively.


The CMC of OCT-PEG6000-b-PLA5000 was quite low (<10−6 mol/L). All micelles were less than 80 nm with spherical shape and high encapsulation efficiency. DTX molecules were well dispersed in the micelles without chemical interactions with the polymers. Flow cytometry and confocal microscopy results showed that OCT-PM-DiI enhanced intracellular delivery efficiency via receptor-mediated endocytosis in NCI-H446 cells; the optimal modification ratio of OCT on micelle surface was 5%. OCT-PM-DTX exhibited higher retardation of tumor growth after intravenous injections into xenograft NCI-H446 tumor model; octreotide-modified micelles did not show severe toxicity.


SSTRs targeting micelles may serve as promising nanocarriers in tumor treatment for hydrophobic anticancer drugs, such as DTX.


antitumor efficacy DTX intracellular delivery octreotide polymeric micelles 



This study was supported by projects from Ministry of Science and Technology, PR China (No. 2009CB930300, No. 2007AA021811, No. 2009ZX09310-001). We thank Dr. Jinfeng Du for his help in preparing the graphs of the manuscript.


  1. 1.
    Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs. 2007;18:95–103.PubMedCrossRefGoogle Scholar
  2. 2.
    Baker J, Ajani J, Scotte F, Winther D, Martin M, Aapro MS, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009;13:49–59.PubMedCrossRefGoogle Scholar
  3. 3.
    Liu B, Yang M, Li R, Ding Y, Qian X, Yu L, et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm. 2008;69:527–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Han X, Liu J, Liu M, Xie C, Zhan C, Gu B, et al. 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int J Pharm. 2009;372:125–31.PubMedCrossRefGoogle Scholar
  5. 5.
    Shao K, Huang R, Li J, Han L, Ye L, J. Lou, et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release. 2010; 147: 118-26.Google Scholar
  6. 6.
    Xiong XB, Uludag H. A. Lavasanifar. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials. 2010; 31: 5886-93.Google Scholar
  7. 7.
    Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci. 2004;61:2549–59.PubMedCrossRefGoogle Scholar
  8. 8.
    Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst. 2003;20:357–403.PubMedCrossRefGoogle Scholar
  9. 9.
    Lin WJ, Chen YC, Lin CC, Chen CF, Chen JW. Characterization of pegylated copolymeric micelles and in vivo pharmacokinetics and biodistribution studies. J Biomed Mater Res B Appl Biomater. 2006;77:188–94.PubMedGoogle Scholar
  10. 10.
    Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.PubMedCrossRefGoogle Scholar
  11. 11.
    Ishihara T, Kubota T, Choi T, Takahashi M, Ayano E, Kanazawa H, et al. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. Int J Pharm. 2009;375:148–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Liu J, Zeng F, Allen C. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. J Control Release. 2005;103:481–97.PubMedCrossRefGoogle Scholar
  13. 13.
    Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.PubMedCrossRefGoogle Scholar
  14. 14.
    Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des. 2002;8:1781–807.PubMedCrossRefGoogle Scholar
  15. 15.
    Weinerand RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs. 2005;19:145–63.CrossRefGoogle Scholar
  16. 16.
    Appetecchiaand M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 29:19.Google Scholar
  17. 17.
    Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683–99.PubMedCrossRefGoogle Scholar
  18. 18.
    Sharmaand K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer. 1998;76:259–66.CrossRefGoogle Scholar
  19. 19.
    Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.PubMedCrossRefGoogle Scholar
  21. 21.
    Huang CM, Wu YT, Chen ST. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem Biol. 2000;7:453–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Watt HL, Kharmate G, Kumar U. Biology of somatostatin in breast cancer. Mol Cell Endocrinol. 2008;286:251–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004;102:61–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005;107:262–75.PubMedCrossRefGoogle Scholar
  25. 25.
    Erchegyi J, Kastin AJ, Zadina JE. Isolation of a novel tetrapeptide with opiate and antiopiate activity from human brain cortex: Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1). Peptides. 1992;13:623–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Beghein N, Rouxhet L, Dinguizli M, Brewster ME, Arien A, Preat V, et al. Characterization of self-assembling copolymers in aqueous solutions using Electron Paramagnetic Resonance and Fluorescence spectroscopy. J Control Release. 2007;117:196–203.PubMedCrossRefGoogle Scholar
  27. 27.
    Elsabahy M, Perron ME, Bertrand N, Yu GE, Leroux JC. Solubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micelles. Biomacromolecules. 2007;8:2250–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Yang M, Ding Y, Zhang L, Qian X, Jiang X, Liu B. Novel thermosensitive polymeric micelles for docetaxel delivery. J Biomed Mater Res A. 2007;81:847–57.PubMedGoogle Scholar
  29. 29.
    Xiong XB, Mahmud A, Uludag H, Lavasanifar A. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. Biomacromolecules. 2007;8:874–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Zeng F, Lee H, Allen C. Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug Chem. 2006;17:399–409.PubMedCrossRefGoogle Scholar
  31. 31.
    Sezgin Z, Yuksel N, Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm. 2006;64:261–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Gu JC, Qiao MX, Gao W, Zhao XL, Hu HY, Xu J, et al. Preparation of adriamycin-loaded temperature/pH sensitive self-assembly block copolymer micelles. Yao Xue Xue Bao. 2009;44:793–7.PubMedGoogle Scholar
  33. 33.
    Cairo CW, Gestwicki JE, Kanai M, Kiessling LL. Control of multivalent interactions by binding epitope density. J Am Chem Soc. 2002;124:1615–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Jule E, Nagasaki Y, Kataoka K. Lactose-installed poly(ethylene glycol)-poly(d, l-lactide) block copolymer micelles exhibit fast-rate binding and high affinity toward a protein bed simulating a cell surface. A surface plasmon resonance study. Bioconjug Chem. 2003;14:177–86.PubMedCrossRefGoogle Scholar
  35. 35.
    Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2008; 128: 23-31.Google Scholar
  36. 36.
    Taxotere® Prescribing Information. Bridgewater, NJ: sanofi-aventis U.S. LLC; Rev. December 2006.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical SciencesPeking UniversityBeijingPeople’s Republic of China

Personalised recommendations